BrECADD Therapy for Hodgkin's Lymphoma
(BrECADD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a combination of six drugs to evaluate their effectiveness for people with advanced Hodgkin's Lymphoma, a type of blood cancer. The drugs include Brentuximab Vedotin (an antibody-drug conjugate), Cyclophosphamide, Dacarbazine, Dexamethasone, Doxorubicin, and Etoposide. Researchers aim to understand the treatment's effectiveness and patient tolerance. They are also exploring whether a blood test can track patient responses to treatment. Ideal participants are those with Stage 2B to Stage IV Hodgkin's Lymphoma who have not received prior treatments for the cancer. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that the BrECADD treatment, which includes Brentuximab Vedotin and other medications, proved safe in earlier studies. When compared to another treatment called eBEACOPP, BrECADD demonstrated much better safety results, with fewer treatment-related issues. Patients generally tolerated the treatment well.
Moreover, Brentuximab Vedotin, a component of BrECADD, is already used in other approved treatments for Hodgkin's Lymphoma. This adds confidence in its safety, as it has been tested in similar contexts.
Overall, current evidence suggests that BrECADD is a well-tolerated option, with manageable side effects for patients who might join this trial.12345Why are researchers excited about this trial's treatments?
Researchers are excited about BrECADD therapy for Hodgkin's Lymphoma because it combines several powerful drugs, including Brentuximab Vedotin, which specifically targets cancer cells with a unique mechanism. Unlike traditional chemotherapies like ABVD or BEACOPP, Brentuximab Vedotin is an antibody-drug conjugate that delivers chemotherapy directly to cancer cells, potentially reducing damage to healthy cells. This targeted approach could lead to fewer side effects and improved outcomes for patients. Additionally, the combination of drugs in BrECADD may enhance the overall effectiveness against Hodgkin's Lymphoma by attacking the cancer in multiple ways simultaneously.
What evidence suggests that the BrECADD therapy could be effective for Hodgkin's Lymphoma?
Research has shown that BrECADD therapy, which participants in this trial will receive, effectively treats advanced Hodgkin's lymphoma. One study demonstrated that this drug combination worked well for younger patients with this cancer. Another study compared BrECADD to a different treatment and found it to be a strong option, especially when PET scans (a type of medical imaging) guided treatment. The BrECADD regimen includes several drugs that work together to attack cancer cells in different ways, aiming to improve patient outcomes. Overall, evidence suggests that BrECADD is a promising treatment choice for Hodgkin's lymphoma.12678
Who Is on the Research Team?
Michele Stanchina, DO
Principal Investigator
University of Miami
Are You a Good Fit for This Trial?
This trial is for adults aged 18-60 with Stage 2 B-IV classical Hodgkin Lymphoma. Participants must have FDG-PET/CT scans showing active disease and an ECOG performance score of ≤2, indicating they can perform daily activities. They should not be pregnant and must agree to use effective contraception during the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the BrECADD regimen, which includes Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of progression-free survival
What Are the Treatments Tested in This Trial?
Interventions
- Brentuximab Vedotin
- Cyclophosphamide
- Dacarbazine
- Dexamethasone
- Doxorubicin
- Etoposide
Trial Overview
The BrECADD therapy being tested combines Brentuximab Vedotin with chemotherapy drugs (Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine) and a steroid (Dexamethasone). The trial aims to evaluate this regimen's effectiveness in treating Hodgkin Lymphoma stages 2B to IV.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants in this group will receive each component of the BrECADD regimen at the recommended dosage listed in the United States Package Inserts (USPIs). Total participation duration is up to 24 months (2 years).
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Miami
Lead Sponsor
Pfizer
Industry Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University
Citations
A Prospective, Multicenter, Single-Arm, Phase II Cohort of ...
... doxorubicin, dacarbazine, and dexamethasone (BrECADD) is highly effective in younger patients with advanced-stage classic Hodgkin lymphoma (AS- ...
a randomised, multicentre, parallel, open-label, phase 3 trial
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, ...
Positron Emission Tomography–Guided Brentuximab ...
Positron emission tomography (PET)-guided therapy with 4-6 cycles of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, ...
5.
lymphomahub.com
lymphomahub.com/medical-information/hd21-phase-iii-trial-fertility-outcomes-in-chl-with-brecadd-vs-ebeacoppFertility outcomes in cHL with BrECADD vs eBEACOPP
Key data: BrECADD showed higher 4-year gonadal function recovery rates vs eBEACOPP in women (95.3% vs 73.3%; hazard ratio [HR], 1.69; 95% ...
European Commission Approves ADCETRIS® ...
The study met its co-primary safety and efficacy endpoints, with BrECADD demonstrating significantly superior safety as assessed by treatment-related morbidity ...
Frontline brentuximab vedotin-based therapy for newly ...
Clinical evidence shows that BV combined with AVD (doxorubicin, vinblastine, dacarbazine) yields superior survival outcomes compared to ABVD, ...
8.
ashpublications.org
ashpublications.org/blood/article/145/3/290/526323/Brentuximab-vedotin-nivolumab-doxorubicin-andBrentuximab vedotin, nivolumab, doxorubicin, and ...
Key PointsWith a median follow-up of 24.2 months, the 2-year progression-free survival of patients treated with AN+AD was 88%.AN+AD led to an 88% CR rate a.
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.